20175-97-7

Usage

Uses

Used in Organic Synthesis:
7-Methoxy-1-tetralone Oxime is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure and functional groups make it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 7-Methoxy-1-tetralone Oxime is used as a key intermediate in the synthesis of various drug candidates. Its presence in the molecular structure can impart specific biological activities, making it a promising candidate for the development of new therapeutic agents.
Used in Agrochemical Industry:
7-Methoxy-1-tetralone Oxime is also utilized in the agrochemical industry for the synthesis of active ingredients in pesticides and other crop protection products. Its unique properties can contribute to the development of novel and effective agrochemicals.

InChI:InChI=1/C11H13NO2/c1-14-9-6-5-8-3-2-4-11(12-13)10(8)7-9/h5-7,13H,2-4H2,1H3/b12-11+

Upstream product

• 6836-19-7 7-Methoxy-1-tetralone 
• 38102-67-9 4-(3-methoxy-phenyl)-4-oxo-butyric acid 
• 100-66-3 methoxybenzene 
• 24743-11-1 4-(m-methoxyphenyl)butanoic acid 

Downstream Products

• 50399-51-4 trans-1,2,3,4-tetrahydro-7-methoxy-1-naphthylamine 
• 553611-27-1 C₁₈H₁₆ClF₃N₂O₂ 
• 887354-63-4 C₁₈H₁₉NO₃S 
• 1439931-08-4 C₃₂H₃₀Cl₄N₂O₃ 
• 22246-71-5 8-methoxy-2,3,4,5-tetrahydro-1H-2-benzazepin-1-one 
• 175357-87-6 N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)diphenylacetamide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction

Histone deacetylase 6 (HDAC6) has become a promising therapeutic target for central nervous system diseases due to its more complex protein structure and biological functions. However, low brain penetration of reported HDAC6 inhibitors limits its clinical application in neurological disorders. Therefore, the benzazepine, a brain-penetrant rigid fragment, was utilized to design a series of selective HDAC6 inhibitors to improve brain bioavailability. Various synthetic strategies were applied to assemble the tetrahydro-benzazepine ring, and 22 compounds were synthesized. Among them, compound 5 showed low nanomolar potency and strong isozyme selectivity for the inhibition of HDAC6 (IC50 = 1.8 nM, 141-fold selectivity over HDAC1) with efficient binding patterns like coordination with the zinc ion and π-π stacking effect. Western blot results showed it could efficiently transport into SH-SY5Y cells and selectively enhance the acetylation level of α-tubulin with a moderate effect on Histone H3. Notably, pharmacokinetic studies demonstrated that compound 5 (brain/plasma ratio of 2.30) had an excellent ability to penetrate the blood-brain barrier of C57 mice. In male rats with transient middle cerebral artery occlusion (MCAO), compound 5 significantly reduced the cerebral infarction from 21.22% to 11.47% and alleviated neurobehavioral deficits in post-ischemic treatment, which provided a strong rationale for pursuing HDAC6-based therapies for ischemic stroke.

Benzo Annulenes as Antiviral Agents

The present disclosure is concerned with benzo annulene compounds that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, chikungunya, Venezuelan equine encephalitis, dengue, influenza, and zika, usi

Catalyst free synthesis of mono- and disubstituted pyrimidines from O-acyl oximes

Transition-metal or iodine catalyzed transformations of O-acyl oximes to various N-heterocycles are well established. Herein, we report a catalyst free, oxime carboxylate based, three-component condensation method to access mono- and disubstituted pyrimidines. A broad range of substituted pyrimidines were prepared in moderate to excellent yields. Control experiments reveal that in situ generated formamidine is the key intermediate.

Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid

Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans (up to 99.9% ee). The absolute configuration of one product was determined by an X-ray crystal structural analysis. We also found a possible mechanism for this reaction.

CARBOXY X RHODAMINE ANALOGS

The present invention provides novel fluorescent dyes and kits containing the same, which are useful for labeling a wide variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes f

Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence

We have identified naphthol derivatives as inhibitors of the vanilloid receptor TRPV1 by high throughput screening. The initial lead showed high clearance in rats and has been optimized by enhancing the acidity of the phenol group. Compound 6b has reduced

TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA

Compounds of formula 1 are disclosed, wherein G, D, A, Q, Y, Z, and R1 through R10 are defined in the specification. Also provided are descriptions of processes for preparing compounds of formula 1, intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

Substituted 1-benzazepines and derivatives thereof

This invention relates to substituted 1-benzazepines and derivatives thereof useful as antibacterial agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and to methods of using these compounds for killing bacteria or inhibiting bacterial growth.

CARBAPENEM DERIVATIVES CONTAINING A BICYCLIC KETONE SUBSTITUENT AND THEIR USE AS ANTI-INFECTIVES

The present invention relates to carbapenems and provides a compound of the formula (I) wherein R1 is hydroxymethyl, 1-hydroxyethyl or 1-fluoroethyl; R2 is hydrogen or C1-4alkyl; X1 is oxygen or sulphur; and A is of the formula which is optionally substituted on either ring and wherein B is of the formula -CH2-C(=0)-(CH2)n-, -C(=0)-(CH2)n1-, -C(=0)-CH=CH-X2-, -C(=O)CH2CH2X2_(CH2)nC(=O)NH- or -CH=CHC(=O)NH wherein n is 1 or 2, n1 is 2 or 3 and X2 is NH, O or S; and a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them